Aidoc Wins Third FDA Breakthrough Nod for CARE CXR Triage

Aidoc has won its third FDA Breakthrough Device Designation in roughly 19 months for a product built on CARE, the AI radiology company's foundation model, the company announced 23 September 2026. The newest designation covers CARE Chest X-Ray (CXR) Triage, software that flags chest X-rays showing possible pneumomediastinum or lobar and lung collapse so a clinician reviews them sooner. The designation speeds FDA's review; it is not a clearance, and several rivals already hold FDA-cleared chest X-ray triage tools of their own.

What one foundation model now covers

Aidoc built its first decade of FDA clearances the conventional way: a separate model, trained on separately annotated data, for each finding it wanted to flag — brain bleeds in 2018, pulmonary embolism in 2019, stroke-causing vessel blockages in 2020, a collapsed lung on X-ray in 2022. CARE, the foundation model Aidoc previewed around RSNA 2024, is built differently. Aidoc describes it as trained through self-supervised learning on a large, real-world imaging dataset without pixel-level annotation for every specific finding, learning to read a full study more the way a radiologist does — comparing priors, weighing context — rather than hunting pixel by pixel for one thing. New findings, the company says, can then be built on the shared CARE backbone faster than training an entirely new model, and a single submission can cover multiple indications for parallel FDA review at once.

Three things CARE is being asked to prove

01

A model, not a point solution

CARE's foundation-model architecture is what let Aidoc bundle 11 new CT-triage indications into a single FDA submission that cleared in January 2026, rather than filing separately for each one — the company's stated rationale for why a shared model should mean faster, broader FDA review.

02

A third designation, three different jobs

The three CARE-built Breakthrough Device Designations span three distinct workflows — broad CT triage, AI-drafted X-ray reporting and now CXR triage — which Aidoc frames as evidence the same underlying model generalizes across anatomies and tasks rather than being tuned to one.

03

Still one designation short of a clearance

CXR Triage's designation accelerates FDA's review queue; it is not itself authorization to market the product. Aidoc's own CT program is the only precedent for how long that gap runs — about four months from designation to clearance.

CARE's first 19 months, in three designations

3rdFDA Breakthrough Device Designation for a CARE-built product since September 2025

2016year Aidoc was founded in Tel Aviv, Israel

$500M+raised by Aidoc across its venture rounds, most recently a $150 million Series E in April 2026

14acute-finding indications Aidoc's CT triage line covers under one FDA clearance as of January 2026

Figures from Aidoc's own announcements and funding disclosures; Aidoc has not published one reconciled figure for its total FDA clearance count.

Pneumomediastinum and a collapsed lung

The chest X-ray is frequently the first imaging study a patient gets, and frequently the first one read by whoever is on shift — a radiology resident, a teleradiologist, an emergency physician working without a radiologist immediately available. CARE CXR Triage is aimed at that variability: it flags studies showing possible pneumomediastinum, air trapped in the chest cavity around the heart, or lobar or lung collapse, so a suspicious study gets bumped up the reading queue regardless of who is covering. Aidoc's stated case for the product is consistency across reader experience levels, not replacing the read itself — a radiologist still makes the call; the software only changes when it lands in front of one.

“Achieving this, while still meeting the most rigorous safety and quality standards, is what makes CARE different.” Idan Bassuk, Chief R&D and AI Officer, Aidoc — in the company's 23 September 2026 announcement

A CXR triage field already FDA-cleared

Aidoc is not entering an empty field. Lunit's INSIGHT CXR Triage holds FDA clearance for chest X-ray triage, trained on more than 160,000 radiographs against CT-confirmed ground truth. Qure.ai's qXR is FDA-cleared for pneumothorax and pleural effusion triage. Annalise.ai says it holds five FDA-cleared chest X-ray findings, more than any other vendor by its own count. GE HealthCare's Critical Care Suite, cleared in 2019, runs its pneumothorax check on the X-ray device itself rather than in the cloud. Every one of those is an FDA clearance; CARE CXR Triage, for now, is a Breakthrough Device Designation — a faster lane through FDA's review, not a finish line already crossed.

CARE CXR Triage against an already-cleared field

Product	Findings flagged	FDA status
CARE CXR Triage (Aidoc)	Pneumomediastinum, lobar/lung collapse	Breakthrough Device Designation, Sep 2026
INSIGHT CXR Triage (Lunit)	Pneumothorax, pleural effusion	510(k) cleared
qXR (Qure.ai)	Pneumothorax, pleural effusion	510(k) cleared
Critical Care Suite (GE HealthCare)	Pneumothorax, on-device image-quality checks	510(k) cleared, 2019

From each company's own labelling and FDA clearance records; not a clinical comparison.

AI radiology's crowded, fast-growing lane

$1.65B → $4.54B

Global AI-in-medical-imaging market, 2024 actual to 2029 forecast, per MarketsandMarkets (2024).

2024 (actual)$1.65B

2029 (forecast)$4.54B

Sources: MarketsandMarkets, AI in Medical Imaging Market · Fortune Business Insights, AI in Radiology Market Size, Share & Industry Analysis

Regulatory News outlook

Chest X-ray triage is one narrow slice of that broader imaging-AI market, already served by at least four FDA-cleared competitors before Aidoc's entry even clears. At a illustrative 5% share of MarketsandMarkets' 2029 forecast, chest-X-ray-triage software alone would be worth on the order of $225 million a year, split across a field CARE CXR Triage has yet to formally join.

How we got here: 5% of MarketsandMarkets' $4.54 billion 2029 AI-in-medical-imaging forecast is $227 million, an illustrative upper-bound slice for the chest-X-ray-triage sub-category specifically, not a company-specific projection.

Ten years, three designations, one model

From a brain-bleed alert to a third designation

1. 2016

   Aidoc founded

   Founded in Tel Aviv, Israel by Elad Walach, Michael Braginsky and Guy Reiner.

2. August 2018

   First FDA clearance

   Deep-learning software to flag intracranial hemorrhage (brain bleed) on CT — Aidoc's first product.

3. 2022

   Pneumothorax clearance

   FDA clearance for a collapsed-lung detector on X-ray, Aidoc's first chest X-ray product.

4. Late 2024

   CARE previewed

   Aidoc introduces CARE, its foundation model, around RSNA 2024.

5. September 2025

   First CARE designation

   FDA Breakthrough Device Designation for a broad CT multi-triage tool spanning numerous indications in one submission.

6. 26 January 2026

   CT triage cleared

   FDA clears 11 new CT-triage indications built on CARE, unified with 3 prior indications into one 14-indication workflow.

7. April 2026

   $150M Series E

   Led by Goldman Sachs Alternatives Growth Equity, with General Catalyst, SoftBank Vision Fund 2 and NVIDIA's NVentures.

8. 25 June 2026

   Second CARE designation

   FDA Breakthrough Device Designation for First Read, AI that drafts preliminary chest X-ray reports for radiologist sign-off.

9. 23 September 2026

   Third CARE designation

   FDA Breakthrough Device Designation for CARE Chest X-Ray (CXR) Triage.

10. Ahead

    A clearance still to file

    Aidoc has not stated a filing date for CXR Triage; its CT program took about four months from designation to clearance.

The gap between designation and clearance

Aidoc's own figures for its business carry real inconsistencies worth naming plainly: the company has cited both roughly 50 million and roughly 60 million patient cases a year across its deployments, and its total FDA clearance count has been reported anywhere from 17 to more than 30 depending on the source, with no single reconciled figure published. FDA does not maintain a public, searchable record of individual Breakthrough Device Designations by name, so this designation — like Aidoc's other two CARE-built ones — rests on the company's own announcement rather than an independent regulatory database entry. And a designation is not a clearance: CARE CXR Triage cannot be marketed or used clinically until it clears FDA review, a step every competitor named above has already completed.

Frequently asked questions

What did FDA grant Aidoc?

A Breakthrough Device Designation, announced 23 September 2026, for CARE Chest X-Ray (CXR) Triage, AI software that flags chest X-rays showing possible pneumomediastinum or lobar/lung collapse for faster clinician review. A Breakthrough Device Designation speeds up FDA's review process; it is not itself a clearance, and CXR Triage is not yet FDA-cleared or on the market.

Why is this Aidoc's third such designation?

It follows a Breakthrough Device Designation for a broad CT multi-triage tool in September 2025 and one for First Read, AI that drafts preliminary chest X-ray reports, on 25 June 2026 — all three built on Aidoc's CARE foundation model, which the company launched around late 2024.

Is Aidoc a public company?

No. Aidoc is privately held, founded in 2016 and headquartered in Tel Aviv, Israel, with a commercial office in New York. It has raised more than $500 million in venture funding, most recently a $150 million Series E in April 2026 led by Goldman Sachs Alternatives.

Who else makes AI for chest X-ray triage?

Lunit, Qure.ai, Annalise.ai and GE HealthCare's on-device Critical Care Suite all already hold FDA clearances for chest X-ray triage software covering findings such as pneumothorax and pleural effusion. Aidoc's CXR Triage, by contrast, holds only a Breakthrough Device Designation so far, not a clearance.